Hereditary prothrombotic states of clinical importance include factor V Leiden, the prothrombin 20210A mutation, deficiencies of protein C, protein S, or antithrombin, sickle cell disease, and hyperhomocysteinemia. Major acquired prothrombotic states include cancer, myeloproliferative disorders, the antiphospholipid syndrome, and heparin-induced thrombocytopenia. Because most of the hereditary prothrombic states are not established risk factors for arterial thrombosis, routine laboratory testing in most patients with ischemic stroke should be limited to complete blood count, lupus anticoagulant, anticardiolipin antibodies, and plasma total homocysteine. Additional testing for factor V Leiden, prothrombin 20210A, antithrombin, protein C, and protein S may be indicated for patients under the age of 50 or those with paradoxical cerebral embolism. The treatment of acute ischemic stroke in patients with prothrombotic states is similar to that in patients without an identifiable prothrombotic condition, and may include antiplatelet agents, anticoagulants, or thrombolytic therapy in patients who otherwise meet eligibility criteria. The potential benefit of chronic anticoagulation therapy for the primary or secondary prevention of stroke in patients with prothrombotic states has not been addressed in controlled clinical trials. Specific therapeutic approaches for the prevention of stroke are established for patients with sickle cell disease, myeloproliferative disorders, and heparininduced thrombocytopenia, and are under investigation for hyperhomocysteinemia and the antiphospholipid syndrome.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
References and Recommended Reading
Kearon C, Crowther M, Hirsh J: Management of patients with hereditary hypercoagulable disorders. Ann Rev Med 2000, 51:169–185. An excellent overview of the hereditary prothrombotic states and their clinical management.
Martinelli I: Risk factors in venous thromboembolism. Thromb Haemost 2001, 86:395–403.
Vandermeer FJM, Koster T, Vandenbroucke JP, et al.: The Leiden thrombophilia study (LETS). Thromb Haemost 1997, 78:631–635. A summary of the Leiden Thrombophilia Study, which was a large case-control study that provided definitive evidence that factor V Leiden and other hereditary prothrombotic states are risk factors for venous thromboembolism.
Reiner AP, Siscovick DS, Rosendaal FR: Hemostatic risk factors and arterial thrombotic disease. Thromb Haemost 2001, 85:584–595. A thorough review of the epidemiologic evidence for an association between hemostatic risk factors and ischemic stroke or myocardial infarction.
Margaglione M, D’Andrea G, Giuliani N, et al.: Inherited prothrombotic conditions and premature ischemic stroke: sex difference in the association with factor V Leiden. Arterioscler ThrombVasc Biol 1999, 19:1751–1756.
Destefano V, Chiusolo P, Paciaroni K, et al.: Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients. Blood 1998, 91:3562–3565.
Steinberg MH: Management of sickle cell disease. N Engl J Med 1999, 340:1021–1030.
Ohene-Frempong K, Weiner SJ, Sleeper LA, et al.: Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 1998, 91:288–294.
Mudd SH, Finkelstein JD, Refsum H, et al.: Homocysteine and its disulfide derivatives: a suggested consensus terminology. Arterioscler Thromb Vasc Biol 2000, 20:1704–1706.
Selhub J: Homocysteine metabolism. Ann Rev Med 1999, 19:217–246.
Eikelboom JW, Lonn E, Genest JJ, et al.: Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 1999, 131:363–375. A systematic review of retrospective and prospective studies examining the association between hyperhomocysteinemia, cardiovascular disease, and cerebrovascular disease.
Eikelboom JW, Hankey GJ, Anand SS, et al.: Association between high homocyst(e)ine and ischemic stroke due to large- and small-artery disease but not other etiologic subtypes of ischemic stroke. Stroke 2000, 31:1069–1075.
Joyce DE: The contribution of prothrombotic states to cancer-related stroke. Semin Cerebrovasc Dis Stroke 2002, In press.
Cortelazzo S, Viero P, Finazzi G, et al.: Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 1990, 8:556–562.
Levine JS, Branch DW, Rauch J: The antiphospholipid syndrome. N Engl J Med 2002, 346:752–763. An authoritative review of current issues related to diagnosis and management of patients with the antiphospholipid syndrome.
Wilson WA, Gharavi AE, Koike T, et al.: International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999, 42:1309–1311.
Petri M: Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun 2000, 15:145–151.
Tuhrim S, Rand JH, Wu XX, et al.: Elevated anticardiolipin antibody titer is a stroke risk factor in a multiethnic population independent of isotype or degree of positivity. Stroke 1999, 30:1561–1565.
Brey RL, Abbott RD, Curb JD, et al.: Beta(2)-glycoprotein I-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the Honolulu heart program. Stroke 2001, 32:1701–1706.
Ginsburg KS, Liang MH, Newcomer L, et al.: Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992, 117:997–1002.
Finazzi G, Brancaccio V, Moia M, et al.: Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med 1996, 100:530–536.
Warkentin TE: Heparin-induced thrombocytopenia: a clinicopathologic syndrome. Thromb Haemost 1999, 82:439–447. An outstanding overview of heparin-induced thrombocytopenia that was written by one of the pioneering investigators who helped define this clinical syndrome.
Warkentin TE, Kelton JG: Delayed-onset heparininduced thrombocytopenia and thrombosis. Ann Intern Med 2002, 135:502–506.
Jacques PF, Selhub J, Bostom AG, et al.: The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Eng J Med 1999, 340:1449–1454.
Brott T, Bogousslavsky J: Treatment of acute ischemic stroke. N Engl J Med 2000, 343:710–722.
Clarke R, Armitage J: Vitamin supplements and cardiovascular risk: review of the randomized trials of homocysteine-lowering vitamin supplements. Semin Thromb Hemost 2000, 26:341–348.
Ware RE, Zimmerman SA, Schultz WH: Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease. Blood 1999, 94:3022–3026.
Refsum H, Ueland PM, Nygård O, Vollset SE: Homocysteine and cardiovascular disease. Annu Rev Med 1998, 49:31–62.
Malinow MR, Bostom AG, Krauss RM: Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 1999, 99:178–182.
Salen DN, Daudelin HD, Levine HL, et al.: Antithrombotic therapy in valvular heart disease. Chest 2001, 119:207S-219S.
Cortelazzo S, Finazzi G, Ruggeri M, et al.: Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995, 332:1132–1136.
Regev A, Stark P, Blickstein D, Lahav M: Thrombotic complications in essential thrombocythemia with relatively low platelet counts. Am J Hematol 1997, 56:168–172.
Pearson TC, Wetherley-Mein G: Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet 1978, 2:1219–1222.
Rosove MH, Brewer PMC: Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992, 117:303–308.
Khamashta MA, Cuadrado MJ, Mujic F, et al.: The management of thrombosis in the antiphospholipidantibody syndrome. N Engl J Med 1995, 332:993–997.
Mohr JP, Thompson JL, Lazar RM, et al.: Warfarinaspirin: a comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 1915, 345:1444–1451.
Moll S, Ortel TL: Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med 1997, 127:177–185.
Tardy-Poncet B, Tardy B, Reynaud J, et al.: Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia. Chest 1999, 115:1616–1620.
Hirsh J, Dalen J, Anderson DR, et al.: Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001, 119:8S-21S.
Adams RJ: Stroke prevention in sickle cell disease. Curr Opin Hematol 2000, 7:101–105. A thorough review of current strategies for the primary and secondary prevention of stroke in patients with sickle cell disease.
Nietert PJ, Abboud MR, Silverstein MD, Jackson SM: Bone marrow transplantation versus periodic prophylactic blood transfusion in sickle cell patients at high risk of ischemic stroke: a decision analysis. Blood 2000, 95:3057–3064.
Greist A: The role of blood component removal in essential and reactive thrombocytosis. Ther Apher 2002, 6:36–44.
About this article
Cite this article
Hiatt, B.K., Lentz, S.R. Prothrombotic states that predispose to stroke. Curr Treat Options Neurol 4, 417–425 (2002). https://doi.org/10.1007/s11940-002-0009-1